CanSino Biologics, Inc. Class H (CJH) Financial Statements
CanSino Biologics, Inc. Class H Financial Overview
CanSino Biologics, Inc. Class H's market cap is currently $1.51B. The company's EPS TTM is $0.12; its P/E ratio is 632.61; CanSino Biologics, Inc. Class H is estimated to report earnings on March 30, 2027, and the estimated EPS forecast is $0.04. See an overview of income statement, balance sheet, and cash flow financials.
| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 1.03B | $ 846.34M | $ 345.18M | $ 1.03B | $ 4.30B |
| Gross Profit | $ 681.82M | $ 601.91M | $ -876.02M | $ -186.61M | $ 3.00B |
| Operating Income | $ -113.12M | $ -375.22M | $ -2.04B | $ -1.37B | $ 1.94B |
| EBITDA | $ 60.98M | $ -163.84M | $ -1.65B | $ -1.30B | $ 1.87B |
| Net Income | $ 27.15M | $ -378.88M | $ -1.48B | $ -909.43M | $ 1.91B |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 2.65B | $ 3.20B | $ 4.12B | $ 5.95B | $ 7.78B |
| Total Assets | $ 7.18B | $ 7.96B | $ 9.32B | $ 11.47B | $ 11.87B |
| Total Debt | $ 1.29B | $ 2.01B | $ 2.70B | $ 2.70B | $ 1.37B |
| Net Debt | $ 52.78M | $ 456.91M | $ 653.34M | $ -694.19M | $ -4.08B |
| Total Liabilities | $ 2.05B | $ 3.05B | $ 4.03B | $ 4.22B | $ 3.33B |
| Stockholders' Equity | $ 4.96B | $ 4.91B | $ 5.27B | $ 6.75B | $ 8.00B |
| Cash Flow | |||||
| Free Cash Flow | $ -152.83M | $ -626.42M | $ -1.53B | $ -2.96B | $ 811.42M |
| Operating Cash Flow | $ 32.49M | $ -168.79M | $ -908.23M | $ -1.89B | $ 2.01B |
| Investing Cash Flow | $ 355.36M | $ 3.96M | $ -449.65M | $ -1.19B | $ -2.53B |
| Financing Cash Flow | $ -703.03M | $ -334.18M | $ -7.58M | $ 854.60M | $ 1.56B |
Currency in CNY
